[(18)F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients

PURPOSE: The aim of this prospective study was to evaluate whether [(18)F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachemi, Mammar, Couturier, Olivier, Vervueren, Laurent, Fosse, Pacôme, Lacœuille, Franck, Urban, Thierry, Hureaux, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914822/
https://www.ncbi.nlm.nih.gov/pubmed/24505298
http://dx.doi.org/10.1371/journal.pone.0087629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914822/
https://www.ncbi.nlm.nih.gov/pubmed/24505298
http://dx.doi.org/10.1371/journal.pone.0087629

Ejemplares similares